Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2015, Article ID 712507, 15 pages
http://dx.doi.org/10.1155/2015/712507
Review Article

The Rise and Fall of Hyaluronan in Respiratory Diseases

1Pediatric Institute, Cleveland Clinic, Cleveland, OH 44195, USA
2Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH 44195, USA
3Department of Pathobiology, Cleveland Clinic, Cleveland, OH 44195, USA
4Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
5National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
6Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA

Received 13 October 2014; Revised 11 February 2015; Accepted 3 May 2015

Academic Editor: Arnoud Sonnenberg

Copyright © 2015 Mark E. Lauer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Petrey and C. A. de la Motte, “Hyaluronan, a crucial regulator of inflammation,” Frontiers in Immunology, vol. 5, article 101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Wang, C. de la Motte, M. Lauer, and V. Hascall, “Hyaluronan matrices in pathobiological processes,” FEBS Journal, vol. 278, no. 9, pp. 1412–1418, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Frey, N. Schroeder, T. Manon-Jensen, R. V. Iozzo, and L. Schaefer, “Biological interplay between proteoglycans and their innate immune receptors in inflammation,” The FEBS Journal, vol. 280, no. 10, pp. 2165–2179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. T. N. Wight, I. Kang, and M. J. Merrilees, “Versican and the control of inflammation,” Matrix Biology, vol. 35, pp. 152–161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Vigetti, E. Karousou, M. Viola, S. Deleonibus, G. de Luca, and A. Passi, “Hyaluronan: biosynthesis and signaling,” Biochimica et Biophysica Acta—General Subjects, vol. 1840, pp. 2452–2459, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Stern, G. Kogan, M. J. Jedrzejas, and L. Šoltés, “The many ways to cleave hyaluronan,” Biotechnology Advances, vol. 25, no. 6, pp. 537–557, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan as an immune regulator in human diseases,” Physiological Reviews, vol. 91, no. 1, pp. 221–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan in tissue injury and repair,” Annual Review of Cell and Developmental Biology, vol. 23, pp. 435–461, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Stern, A. A. Asari, and K. N. Sugahara, “Hyaluronan fragments: an information-rich system,” European Journal of Cell Biology, vol. 85, no. 8, pp. 699–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-G. Wisniewski and J. Vilček, “TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity,” Cytokine and Growth Factor Reviews, vol. 8, no. 2, pp. 143–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Fries and A. Kaczmarczyk, “Inter-α-inhibitor, hyaluronan and inflammation,” Acta Biochimica Polonica, vol. 50, no. 3, pp. 735–742, 2003. View at Google Scholar · View at Scopus
  12. C. M. Milner and A. J. Day, “TSG-6: a multifunctional protein associated with inflammation,” Journal of Cell Science, vol. 116, no. 10, pp. 1863–1873, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Milner, V. A. Higman, and A. J. Day, “TSG-6: a pluripotent inflammatory mediator?” Biochemical Society Transactions, vol. 34, no. 3, pp. 446–450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Milner, W. Tongsoongnoen, M. S. Rugg, and A. J. Day, “The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan,” Biochemical Society Transactions, vol. 35, no. 4, pp. 672–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Swaidani, G. Cheng, M. E. Lauer et al., “TSG-6 protein is crucial for the development of pulmonary hyaluronan deposition, eosinophilia, and airway hyperresponsiveness in a murine model of asthma,” The Journal of Biological Chemistry, vol. 288, no. 1, pp. 412–422, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Lauer, M. Aytekin, S. A. Comhair et al., “Modification of hyaluronan by heavy chains of inter-α-inhibitor in idiopathic pulmonary arterial hypertension,” Journal of Biological Chemistry, vol. 289, no. 10, pp. 6791–6798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Garantziotis, E. Zudaire, C. S. Trempus et al., “Serum inter-α-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 9, pp. 939–947, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. F. E. Lennon and P. A. Singleton, “Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 301, no. 2, pp. L137–L147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. O. Cantor, “Potential therapeutic applications of hyaluronan in the lung,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 2, pp. 283–288, 2007. View at Google Scholar
  20. S. Haserodt, A. Metin, and R. A. Dweik, “A comparison of the sensitivity, specificity, and molecular weight accuracy of three different commercially available hyaluronan ELISA-like assays,” Glycobiology, vol. 21, no. 2, pp. 175–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Bjermer, A. Engström-Laurent, R. Lundgren, L. Rosenhall, and R. Hällgren, “Hyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmer's lung,” British Medical Journal, vol. 295, no. 6602, pp. 803–806, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Cormier, M. Laviolette, A. Cantin, G. M. Tremblay, and R. Bégin, “Fibrogenic activities in bronchoalveolar lavage fluid of farmer's lung,” Chest, vol. 104, no. 4, pp. 1038–1042, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Larsson, A. Eklund, P. Malmberg, L. Bjermer, R. Lundgren, and L. Belin, “Hyaluronic acid (hyaluronan) in BAL fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis,” Chest, vol. 101, no. 1, pp. 109–114, 1992. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Larsson, A. Eklund, P. Malmberg, and L. Belin, “Alterations in bronchoalveolar lavage fluid but not in lung function and bronchial responsiveness in swine confinement workers,” Chest, vol. 101, no. 3, pp. 767–774, 1992. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Brouwer, K. Biersteker, P. Bongers, B. Remijn, and D. Houthuijs, “Respiratory symptoms, lung function, and IgG4 levels against pig antigens in a sample of Dutch pig farmers,” The American Journal of Industrial Medicine, vol. 10, no. 3, pp. 283–285, 1986. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Iversen, R. Dahl, J. Korsgaard, T. Hallas, and E. J. Jensen, “Respiratory symptoms in Danish farmers: an epidemiological study of risk factors,” Thorax, vol. 43, no. 11, pp. 872–877, 1988. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Larsson, P. Malmberg, A. Eklund, L. Belin, and E. Blaschke, “Exposure to microorganisms, airway inflammatory changes and immune reactions in asymptomatic dairy farmers. Bronchoalveolar lavage evidence of macrophage activation and permeability changes in the airways,” International Archives of Allergy and Applied Immunology, vol. 87, no. 2, pp. 127–133, 1988. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Wimander and L. Belin, “Recognition of allergic alveolitis in the trimming department of a Swedish sawmill,” European Journal of Respiratory Diseases. Supplement, vol. 107, pp. 163–167, 1980. View at Google Scholar · View at Scopus
  29. U. Johard, A. Eklund, M. Dahlqvist et al., “Signs of alveolar inflammation in non-smoking Swedish wood trimmers,” British Journal of Industrial Medicine, vol. 49, no. 6, pp. 428–434, 1992. View at Google Scholar · View at Scopus
  30. U. Johard, A. Eklund, J. Hed et al., “Sawdust-induced inflammatory changes in rat lung: effects on alveolar and interstitial cells in relation to time,” Inflammation, vol. 18, no. 5, pp. 547–563, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Sparrow, R. Bossé, B. Rosner, and S. T. Weiss, “The effect of occupational exposure on pulmonary function. A longitudinal evaluation of fire fighters and nonfire fighters,” American Review of Respiratory Disease, vol. 125, no. 3, pp. 319–322, 1982. View at Google Scholar · View at Scopus
  32. P. W. Brandt-Rauf, B. Cosman, L. F. Fallon Jr., T. Tarantini, and C. Idema, “Health hazards of firefighters: acute pulmonary effects after toxic exposures,” British Journal of Industrial Medicine, vol. 46, no. 3, pp. 209–211, 1989. View at Google Scholar · View at Scopus
  33. C. E. Bergström, A. Eklund, M. Sköld, and G. Tornling, “Bronchoalveolar lavage findings in firefighters,” American Journal of Industrial Medicine, vol. 32, no. 4, pp. 332–336, 1997. View at Google Scholar · View at Scopus
  34. J. E. Alleman and B. T. Mossman, “Asbestos revisited,” Scientific American, vol. 277, pp. 54–57, 1997. View at Publisher · View at Google Scholar
  35. E. Jamrozik, N. de Klerk, and A. W. Musk, “Asbestos-related disease,” Internal Medicine Journal, vol. 41, no. 5, pp. 372–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. M. Cantin, P. Larivée, M. Martel, and R. Bégin, “Hyaluronan (hyaluronic acid) in lung lavage of asbestos-exposed humans and sheep,” Lung, vol. 170, no. 4, pp. 211–220, 1992. View at Google Scholar · View at Scopus
  37. E. Pluygers, P. Baldewyns, P. Minette, M. Beauduin, P. Gourdin, and P. Robinet, “Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations,” European Journal of Cancer Prevention, vol. 1, no. 1, pp. 57–68, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Brisman, K. Torén, L. Lillienberg, G. Karlsson, and S. Ahlstedt, “Nasal symptoms and indices of nasal inflammation in flour-dust-exposed bakers,” International Archives of Occupational and Environmental Health, vol. 71, no. 8, pp. 525–532, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Garantziotis, Z. Li, E. N. Potts et al., “Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice,” The Journal of Biological Chemistry, vol. 284, no. 17, pp. 11309–11317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Garantziotis, Z. Li, E. N. Potts et al., “TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 666–675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Ormiston, G. R. D. Slaughter, Y. Deng, D. J. Stewart, and D. W. Courtman, “The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 298, no. 2, pp. L148–L157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. R. Bracke, M. A. Dentener, E. Papakonstantinou et al., “Enhanced deposition of low-molecular-weight hyaluronan in lungs of cigarette smoke—exposed mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 6, pp. 753–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Liang, D. Jiang, Y. Jung et al., “Role of hyaluronan and hyaluronan-binding proteins in human asthma,” Journal of Allergy and Clinical Immunology, vol. 128, no. 2, pp. 403.e3–411.e3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Eldridge, A. Moldobaeva, and E. M. Wagner, “Increased hyaluronan fragmentation during pulmonary ischemia,” The American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 301, no. 5, pp. L782–L788, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. T. Kuipers, T. van der Poll, M. J. Schultz, and C. W. Wieland, “Bench-to-bedside review: damage-associated molecular patterns in the onset of ventilator-induced lung injury,” Critical Care, vol. 15, article 235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. A. McDevitt, G. J. Beck, M. J. Ciunga, and J. O'Brien, “Cigarette smoke degrades hyaluronic acid,” Lung, vol. 167, no. 1, pp. 237–245, 1989. View at Publisher · View at Google Scholar · View at Scopus
  47. R. R. Kew, B. Ghebrehiwet, and A. Janoff, “Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement,” The Journal of Clinical Investigation, vol. 75, no. 3, pp. 1000–1007, 1985. View at Publisher · View at Google Scholar · View at Scopus
  48. C. M. Sköld, E. Blaschke, and A. Eklund, “Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms,” Respiratory Medicine, vol. 90, no. 9, pp. 523–529, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Decramer, W. Janssens, and M. Miravitlles, “Chronic obstructive pulmonary disease,” The Lancet, vol. 379, no. 9823, pp. 1341–1351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. W. D. Song, A. C. Zhang, Y. Y. Pang et al., “Fibronectin and hyaluronan in bronchoalveolar lavage fluid from young patients with chronic obstructive pulmonary diseases,” Respiration, vol. 62, no. 3, pp. 125–129, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Dentener, J. H. J. Vernooy, S. Hendriks, and E. F. M. Wouters, “Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation,” Thorax, vol. 60, no. 2, pp. 114–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. Elias, C. G. Lee, T. Zheng, B. Ma, R. J. Homer, and Z. Zhu, “New insights into the pathogenesis of asthma,” The Journal of Clinical Investigation, vol. 111, no. 3, pp. 291–297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Sahu and W. S. Lynn, “Hyaluronic acid in the pulmonary secretions of patients with asthma,” Biochemical Journal, vol. 173, no. 2, pp. 565–568, 1978. View at Google Scholar · View at Scopus
  54. A. M. Vignola, P. Chanez, A. M. Campbell et al., “Airway inflammation in mild intermittent and in persistent asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 2, pp. 403–409, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. A. G. Ayars, L. C. Altman, S. Potter-Perigo, K. Radford, T. N. Wight, and P. Nair, “Sputum hyaluronan and versican in severe eosinophilic asthma,” International Archives of Allergy and Immunology, vol. 161, no. 1, pp. 65–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.-Y. Brillet, and J. Müller-Quernheim, “Sarcoidosis,” The Lancet, vol. 383, no. 9923, pp. 1155–1167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Hallgren, A. Eklund, A. Engstrom-Laurent, and B. Schmekel, “Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease,” British Medical Journal, vol. 290, no. 6484, pp. 1778–1781, 1985. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Eklund, R. Hällgren, E. Blaschke, A. Engström-Laurent, U. Persson, and B. Svane, “Hyaluronate in bronchoalveolar lavage fluid in sarcoidosis and its relationship to alveolar cell populations,” European Journal of Respiratory Diseases, vol. 71, no. 1, pp. 30–36, 1987. View at Google Scholar · View at Scopus
  59. L. Bjermer, A. Engstrom-Laurent, M. Thunell, and R. Hallgren, “Hyaluronic acid in bronchoalveolar lavage fluid in patients with sarcoidosis: relationship to lavage mast cells,” Thorax, vol. 42, no. 12, pp. 933–938, 1987. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Blaschke, A. Eklund, and R. Hernbrand, “Extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis and their relationship to signs of alveolitis,” American Review of Respiratory Disease, vol. 141, no. 4 I, pp. 1020–1025, 1990. View at Publisher · View at Google Scholar · View at Scopus
  61. P. J. Wolters, H. R. Collard, and K. D. Jones, “Pathogenesis of idiopathic pulmonary fibrosis,” Annual Review of Pathology, vol. 9, pp. 157–179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Bjermer, R. Lundgren, and R. Hallgren, “Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis,” Thorax, vol. 44, no. 2, pp. 126–131, 1989. View at Publisher · View at Google Scholar · View at Scopus
  63. N. Milman, M. S. Kristensen, and K. Bentsen, “Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis,” APMIS, vol. 103, no. 10, pp. 749–754, 1995. View at Publisher · View at Google Scholar · View at Scopus
  64. Z. W. Ghamra and R. A. Dweik, “Primary pulmonary hypertension: an overview of epidemiology and pathogenesis,” Cleveland Clinic Journal of Medicine, vol. 70, no. 1, pp. S2–S8, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Papakonstantinou, F. M. Kouri, G. Karakiulakis, I. Klagas, and O. Eickelberg, “Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension,” European Respiratory Journal, vol. 32, no. 6, pp. 1504–1512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Aytekin, S. A. A. Comhair, C. de la Motte et al., “High levels of hyaluronan in idiopathic pulmonary arterial hypertension,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 295, no. 5, pp. L789–L799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. P. N. Rao, A. Zeevi, J. Snyder et al., “Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation,” Journal of Heart and Lung Transplantation, vol. 13, no. 6, pp. 958–962, 1994. View at Google Scholar · View at Scopus
  68. G. C. Riise, C. Kjellström, W. Ryd et al., “Inflammatory cells and activation markers in BAL during acute rejection and infection in lung transplant recipients: a prospective, longitudinal study,” European Respiratory Journal, vol. 10, no. 8, pp. 1742–1746, 1997. View at Publisher · View at Google Scholar · View at Scopus
  69. G. C. Riise, H. Scherstén, F. Nilsson, W. Ryd, and B. A. Andersson, “Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL: association with acute rejection in lung transplant recipients,” Chest, vol. 110, no. 1, pp. 89–96, 1996. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Estenne, J. R. Maurer, A. Boehler et al., “Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria,” Journal of Heart and Lung Transplantation, vol. 21, no. 3, pp. 297–310, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. J. L. Todd, X. Wang, S. Sugimoto et al., “Hyaluronan Contributes to Bronchiolitis Obliterans Syndrome and Stimulates Lung Allograft Rejection through Activation of Innate Immunity,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 5, pp. 556–566, 2014. View at Publisher · View at Google Scholar
  72. J. E. Adair, V. Stober, M. Sobhany et al., “Inter-α-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding,” The Journal of Biological Chemistry, vol. 284, no. 25, pp. 16922–16930, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Garantziotis, J. W. Hollingsworth, R. B. Ghanayem et al., “Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury,” The Journal of Immunology, vol. 179, no. 6, pp. 4187–4192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Cheng, S. Swaidani, M. Sharma, M. E. Lauer, V. C. Hascall, and M. A. Aronica, “Hyaluronan deposition and correlation with inflammation in a murine ovalbumin model of asthma,” Matrix Biology, vol. 30, no. 2, pp. 126–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Cheng, S. Swaidani, M. Sharma, M. E. Lauer, V. C. Hascall, and M. A. Aronica, “Correlation of hyaluronan deposition with infiltration of eosinophils and lymphocytes in a cockroach-induced murine model of asthma,” Glycobiology, vol. 23, no. 1, pp. 43–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Ghosh, A. E. Samarasinghe, S. A. Hoselton, G. P. Dorsam, and J. M. Schuh, “Hyaluronan deposition and co-localization with inflammatory cells and collagen in a murine model of fungal allergic asthma,” Inflammation Research, vol. 63, no. 6, pp. 475–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. M. E. Lauer, G. Cheng, S. Swaidanis, M. A. Aronica, P. H. Weigel, and V. C. Hascall, “Tumor necrosis factor-stimulated gene-6 (TSG-6) amplifies hyaluronan synthesis by airway smooth muscle cells,” Journal of Biological Chemistry, vol. 288, no. 1, pp. 423–431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Chua, J. Gauldie, and G. J. Laurent, “Pulmonary fibrosis: searching for model answers,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 1, pp. 9–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. R. T. Dorr, “Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics,” Seminars in Oncology, vol. 19, no. 2, pp. 3–8, 1992. View at Google Scholar · View at Scopus
  80. O. Nettelbladt, J. Bergh, M. Schenholm, A. Tengblad, and R. Hallgren, “Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis,” American Review of Respiratory Disease, vol. 139, no. 3, pp. 759–762, 1989. View at Publisher · View at Google Scholar · View at Scopus
  81. O. Nettelbladt, A. Tengblad, and R. Hallgren, “High-dose corticosteroids during bleomycin-induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue,” European Respiratory Journal, vol. 3, no. 4, pp. 421–428, 1990. View at Google Scholar · View at Scopus
  82. B. A. Bray, P. M. Sampson, M. Osman, A. Giandomenico, and G. M. Turino, “Early changes in lung tissue hyaluronan (hyaluronic acid) and hyaluronidase in bleomycin-induced alveolitis in hamsters,” American Review of Respiratory Disease, vol. 143, no. 2, pp. 284–288, 1991. View at Publisher · View at Google Scholar · View at Scopus
  83. O. Nettelbladt, A. Scheynius, J. Bergh, A. Tengblad, and R. Hällgren, “Alveolar accumulation of hyaluronan and alveolar cellular response in bleomycin-induced alveolitis,” European Respiratory Journal, vol. 4, no. 4, pp. 407–414, 1991. View at Google Scholar · View at Scopus
  84. P. Teder, R. W. Vandivier, D. Jiang et al., “Resolution of lung inflammation by CD44,” Science, vol. 296, no. 5565, pp. 155–158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. A. M. Dygai, E. G. Skurikhin, N. N. Ermakova et al., “Antifibrotic activity of hyaluronidase immobilized on polyethylenoxide under conditions of bleomycin-induced pneumofibrosis,” Bulletin of Experimental Biology and Medicine, vol. 154, no. 3, pp. 388–392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. O. Nettelbladt, K. Lundberg, A. Tengblad, and R. Hällgren, “Accumulation of hyaluronan in bronchoalveolar lavage fluid is independent of iron-, complement- and granulocyte-depletion in bleomycin-induced alveolitis in the rat,” European Respiratory Journal, vol. 3, no. 7, pp. 765–771, 1990. View at Google Scholar · View at Scopus
  87. J. Hernnas, O. Nettelbladt, L. Bjermer, B. Sarnstrand, A. Malmstrom, and R. Hallgren, “Alveolar accumulation of fibronectin and hyaluronan precedes bleomyin-induced pulmonary fibrosis in the rat,” European Respiratory Journal, vol. 5, no. 4, pp. 404–410, 1992. View at Google Scholar · View at Scopus
  88. A. Zaman, Z. Cui, J. P. Foley et al., “Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 5, pp. 447–454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. R. C. Savani, G. Hou, P. Liu et al., “A role for hyaluronan in macrophage accumulation and collagen deposition after bleomycin-induced lung injury,” The American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 4, pp. 475–484, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. H.-W. Zhao, L. Ü. Chang-Jun, and R.-J. Yu, “An increase in hyaluronan by lung fibroblasts: a biomarker for intensity and activity of interstitial pulmonary fibrosis?” Respirology, vol. 4, no. 2, pp. 131–138, 1999. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Teder, O. Nettelbladt, and P. Heldin, “Characterization of the mechanism involved in bleomycin-induced increased hyaluronan production in rat lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 12, no. 2, pp. 181–189, 1995. View at Publisher · View at Google Scholar · View at Scopus
  92. I. N. Zelko and R. J. Folz, “Extracellular superoxide dismutase attenuates release of pulmonary hyaluronan from the extracellular matrix following bleomycin exposure,” FEBS Letters, vol. 584, no. 13, pp. 2947–2952, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. M. A. Antunes and P. R. M. Rocco, “Elastase-induced pulmonary emphysema: insights from experimental models,” Anais da Academia Brasileira de Ciencias, vol. 83, no. 4, pp. 1385–1395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Moczar, C. Lafuma, F. Lange, J. Bignon, L. Robert, and E. Moczar, “Glycosaminoglycans in elastase induced emphysema,” Bulletin Européen de Physiopathologie Respiratoire, vol. 16, supplement, pp. 99–104, 1980. View at Google Scholar
  95. J. O. Cantor, J. M. Cerreta, S. Keller, and G. M. Turino, “Modulation of airspace enlargement in elastase-induced emphysema by intratracheal instillment of hyaluronidase and hyaluronic acid,” Experimental Lung Research, vol. 21, no. 3, pp. 423–436, 1995. View at Publisher · View at Google Scholar · View at Scopus
  96. J. O. Cantor, J. M. Cerreta, G. Armand, and G. M. Turino, “Further investigation of the use of intratracheally administered hyaluronic acid to ameliorate elastase-induced emphysema,” Experimental Lung Research, vol. 23, no. 3, pp. 229–244, 1997. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Scuri, W. M. Abraham, Y. Botvinnikova, and R. Forteza, “Hyaluronic acid blocks porcine pancreatic elastase (PPE)-induced bronchoconstriction in sheep,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, pp. 1855–1859, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Scuri and W. M. Abraham, “Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep,” Pulmonary Pharmacology and Therapeutics, vol. 16, no. 6, pp. 335–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Scuri, J. R. Sabater, and W. M. Abraham, “Hyaluronan blocks porcine pancreatic elastase-induced mucociliary dysfunction in allergic sheep,” Journal of Applied Physiology, vol. 102, no. 6, pp. 2324–2331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Negrini, A. Passi, G. De Luca, and G. Miserocchi, “Proteoglycan involvement during development of lesional pulmonary edema,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 274, no. 2, pp. L203–L211, 1998. View at Google Scholar · View at Scopus
  101. A. Passi, D. Negrini, R. Albertini, G. de Luca, and G. Miserocchi, “Involvement of lung interstitial proteoglycans in development of hydraulic- and elastase-induced edema,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 275, no. 3, pp. L631–L635, 1998. View at Google Scholar · View at Scopus
  102. R. D. Bland, “Edema formation in the lungs and its relationship to neonatal respiratory distress,” Acta Paediatrica, vol. 72, supplement 305, pp. 92–99, 1983. View at Publisher · View at Google Scholar · View at Scopus
  103. S. E. Juul, R. C. Krueger Jr., L. Scofield, M. B. Hershenson, and N. B. Schwartz, “Hyperoxia alone causes changes in lung proteoglycans and hyaluronan in neonatal rat pups,” American Journal of Respiratory Cell and Molecular Biology, vol. 13, no. 6, pp. 629–638, 1995. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Johnsson, L. Eriksson, A. Jonzon, T. C. Laurent, and G. Sedin, “Lung hyaluronan and water content in preterm and term rabbit pups exposed to oxygen or air,” Pediatric Research, vol. 44, no. 5, pp. 716–722, 1998. View at Publisher · View at Google Scholar · View at Scopus
  105. R. L. Stedman, “The chemical composition of tobacco and tobacco smoke,” Chemical Reviews, vol. 68, no. 2, pp. 153–207, 1968. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Vassallo and J. H. Ryu, “Smoking-related interstitial lung diseases,” Clinics in Chest Medicine, vol. 33, no. 1, pp. 165–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. J. O. Cantor, J. M. Cerreta, M. Ochoa, S. Ma, M. Liu, and G. M. Turino, “Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?” Lung, vol. 189, no. 1, pp. 51–56, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. P.-M. Huang, O. Syrkina, L. Yu et al., “High MW hyaluronan inhibits smoke inhalation-induced lung injury and improves survival,” Respirology, vol. 15, no. 7, pp. 1131–1139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Bao, L. Liang, F. Li, M. Zhang, and X. Zhou, “Effects of acute ozone exposure on lung peak allergic inflammation of mice,” Frontiers in Bioscience, vol. 18, no. 3, pp. 838–851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. F. Feng, Z. Li, E. N. Potts-Kant et al., “Hyaluronan activation of the Nlrp3 inflammasome contributes to the development of airway hyperresponsiveness,” Environmental Health Perspectives, vol. 120, no. 12, pp. 1692–1698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. Z. Li, E. N. Potts-Kant, S. Garantziotis, W. M. Foster, and J. W. Hollingsworth, “Hyaluronan signaling during ozone-induced lung injury requires TLR4, MyD88, and TIRAP,” PLoS ONE, vol. 6, no. 11, Article ID e27137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. Z. Li, E. N. Potts, C. A. Piantadosi, W. M. Foster, and J. W. Hollingsworth, “Hyaluronan fragments contribute to the ozone-primed immune response to lipopolysaccharide,” The Journal of Immunology, vol. 185, no. 11, pp. 6891–6898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. R. P. Hill, “Radiation effects on the respiratory system,” BJR Supplement, vol. 27, pp. 75–81, 2005. View at Google Scholar
  114. D. Rosenbaum, S. Peric, M. Holecek, and H. E. Ward, “Hyaluronan in radiation-induced lung disease in the rat,” Radiation Research, vol. 147, no. 5, pp. 585–591, 1997. View at Publisher · View at Google Scholar · View at Scopus
  115. Y. Li, M. Rahmanian, C. Widström, G. Lepperdinger, G. I. Frost, and P. Heldin, “Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression,” American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 3, pp. 411–418, 2000. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Iwakawa, S. Noda, T. Ohta et al., “Strain dependent differences in a histological study of CD44 and collagen fibers with an expression analysis of inflammatory response-related genes in irradiated murine lung,” Journal of Radiation Research, vol. 45, no. 3, pp. 423–433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. S. E. Juul, M. G. Kinsella, J. C. Jackson, W. E. Truog, T. A. Standaert, and W. A. Hodson, “Changes in hyaluronan deposition during early respiratory distress syndrome in premature monkeys,” Pediatric Research, vol. 35, no. 2, pp. 238–243, 1994. View at Publisher · View at Google Scholar · View at Scopus
  118. K. J. Bai, A. P. Spicer, M. M. Mascarenhas et al., “The role of hyaluronan synthase 3 in ventilator-induced lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 1, pp. 92–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. X. Wang, Z. Sun, L. Qian et al., “Effects of hyaluronan-fortified surfactant in ventilated premature piglets with respiratory distress,” Biology of the Neonate, vol. 89, no. 1, pp. 15–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Baron, Ed., Medical Microbiology, University of Texas Medical Branch at Galveston, Galveston, Tex, USA, 1996, http://www.ncbi.nlm.nih.gov/books/NBK7627/.
  121. S. E. Juul, M. G. Kinsella, W. E. Truog, R. L. Gibson, and G. J. Redding, “Lung hyaluronan decreases during Group B Streptococcal pneumonia in neonatal piglets,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 5, pp. 1567–1570, 1996. View at Publisher · View at Google Scholar · View at Scopus
  122. G. J. W. van der Windt, S. Florquin, A. F. de Vos et al., “CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during gram-negative pneumonia,” The American Journal of Pathology, vol. 177, no. 5, pp. 2483–2494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. G. J. W. van der Windt, A. J. Hoogendijk, A. F. de vos, M. E. Kerver, S. Florquin, and T. Van Der Poll, “The role of CD44 in the acute and resolution phase of the host response during pneumococcal pneumonia,” Laboratory Investigation, vol. 91, no. 4, pp. 588–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. Z. Hasan, K. Palani, M. Rahman, and H. Thorlacius, “Targeting CD44 expressed on neutrophils inhibits lung damage in abdominal sepsis,” Shock, vol. 35, no. 6, pp. 567–572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. C. Marion, J. M. Stewart, M. F. Tazi et al., “Streptococcus pneumoniae can utilize multiple sources of hyaluronic acid for growth,” Infection and Immunity, vol. 80, no. 4, pp. 1390–1398, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. O. N. Uchakina, C. M. Castillejo, C. C. Bridges, and R. J. McKallip, “The role of hyaluronic acid in SEB-induced acute lung inflammation,” Clinical Immunology, vol. 146, no. 1, pp. 56–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. R. J. McKallip, H. F. Hagele, and O. N. Uchakina, “Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation,” Toxins, vol. 5, no. 10, pp. 1814–1826, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Y. Chang, Y. Tanino, V. Vidova et al., “Reprint of: a rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease,” Matrix Biology, vol. 35, pp. 162–173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. L. Zhuo, A. Kanamori, R. Kannagi et al., “SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum,” The Journal of Biological Chemistry, vol. 281, no. 29, pp. 20303–20314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. H. He, S. Zhang, S. Tighe, J. Son, and S. C. G. Tseng, “Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharide-activated macrophages toward m2 phenotype,” The Journal of Biological Chemistry, vol. 288, no. 36, pp. 25792–25803, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. M. E. Monzon, S. Casalino-Matsuda, and R. M. Forteza, “Identification of glycosaminoglycans in human airway secretions,” The American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 135–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. C. B. Basbaum and W. E. Finkbeiner, “Airway secretion: a cell-specific analysis,” Hormone and Metabolic Research, vol. 20, no. 11, pp. 661–667, 1988. View at Publisher · View at Google Scholar · View at Scopus
  133. J. N. Baraniuk, T. Shizari, M. Sabol, M. Ali, and C. B. Underhill, “Hyaluronan is exocytosed from serous, but not mucous cells, of human nasal and tracheobronchial submucosal glands,” Journal of Investigative Medicine, vol. 44, no. 2, pp. 47–52, 1996. View at Google Scholar · View at Scopus
  134. J. O. Cantor, J. M. Cerreta, G. Armand, and G. M. Turino, “Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase,” Proceedings of the Society for Experimental Biology and Medicine, vol. 217, no. 4, pp. 471–475, 1998. View at Publisher · View at Google Scholar · View at Scopus
  135. J. O. Cantor and G. M. Turino, “Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema?” Chest, vol. 125, no. 1, pp. 288–292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  136. P. P. Nadkarni, G. S. Kulkarni, J. M. Cerreta, S. Ma, and J. O. Cantor, “Dichotomous effect of aerosolized hyaluronan in a hamster model of endotoxin-induced lung injury,” Experimental Lung Research, vol. 31, no. 9-10, pp. 807–818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. J. O. Cantor, J. M. Cerreta, M. Ochoa et al., “Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema,” Experimental Lung Research, vol. 31, no. 4, pp. 417–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Petrigni and L. Allegra, “Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma,” Pulmonary Pharmacology & Therapeutics, vol. 19, no. 3, pp. 166–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. C. Sondrup, Y. Liu, X. Z. Shu, G. D. Prestwich, and M. E. Smith, “Cross-linked hyaluronan-coated stents in the prevention of airway stenosis,” Otolaryngology—Head and Neck Surgery, vol. 135, no. 1, pp. 28–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. H. W. Taeusch, E. Dybbro, and K. W. Lu, “Pulmonary surfactant adsorption is increased by hyaluronan or polyethylene glycol,” Colloids and Surfaces B: Biointerfaces, vol. 62, no. 2, pp. 243–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. Y.-Y. Liu, C.-H. Lee, R. Dedaj et al., “High-molecular-weight hyaluronan—a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats,” Critical Care, vol. 12, no. 4, article R102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Buonpensiero, F. de Gregorio, A. Sepe et al., “Hyaluronic acid improves ‘pleasantness’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis,” Advances in Therapy, vol. 27, no. 11, pp. 870–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. J.-M. Zahm, M. Milliot, A. Bresin, C. Coraux, and P. Birembaut, “The effect of hyaluronan on airway mucus transport and airway epithelial barrier integrity: potential application to the cytoprotection of airway tissue,” Matrix Biology, vol. 30, no. 7-8, pp. 389–395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. L. M. Carro, A. L. Ferreiro, M. R. de Valbuena Máiz, C. W. Struwing, G. G. Álvarez, and L. S. Cortina, “Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis,” Medicina Clinica, vol. 138, no. 2, pp. 57–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. M. L. Furnari, L. Termini, G. Traverso et al., “Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study,” Therapeutic Advances in Respiratory Disease, vol. 6, no. 6, pp. 315–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Macchi, P. Terranova, E. Digilio, and P. Castelnuovo, “Hyaluronan plus saline nasal washes in the treatment of rhino-sinusal symptoms in patients undergoing functional endoscopic sinus surgery for rhino-sinusal remodeling,” International Journal of Immunopathology and Pharmacology, vol. 26, no. 1, pp. 137–145, 2013. View at Google Scholar · View at Scopus
  147. F. Cresta, A. Naselli, F. Favilli, and R. Casciaro, “Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance,” BMJ Case Reports, vol. 2013, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. K. W. Lu, H. W. Taeusch, and J. A. Clements, “Hyaluronan with dextran added to therapeutic lung surfactants improves effectiveness in vitro and in vivo,” Experimental Lung Research, vol. 39, no. 4-5, pp. 191–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Macchi, P. Castelnuovo, P. Terranova, and E. Digilio, “Effects of sodium hyaluronate in children with recurrent upper respiratory tract infections: results of a randomised controlled study,” International Journal of Immunopathology and Pharmacology, vol. 26, no. 1, pp. 127–135, 2013. View at Google Scholar · View at Scopus
  150. M. Ros, R. Casciaro, F. Lucca et al., “Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial,” Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 27, no. 2, pp. 133–137, 2014. View at Publisher · View at Google Scholar · View at Scopus